Disease in humans involves a complicated interplay of pathology expressed on each individual’s unique genetic and phenotypic backdrop. The exponential growth of genomic, transcriptomic, and proteomic single-cell technologies provides unprecedented opportunities to capture and understand this complexity. Mass cytometry in particular—a flow cytometry platform that enables simultaneous measurement of over 50 parameters per cell (1–3)—holds significant promise to identify molecular signatures that underlie clinical outcomes (4,5), to help monitor disease progression (6), and to predict therapeutic responses (7,8). However, as the dimensionality of mass cytometry datasets increases, the development of appropriate computational approaches and standardized protocols becomes paramount (9). In this special issue published jointly with Cytometry A (10), we explore the necessary steps to transform mass cytometry from a technological tour-de-force to a valuable clinical platform. We highlight six studies that illustrate recent progress. The manuscripts by Yao et al. (11), Corneau et al. (12), and Strauss-Albee et al. (13) emphasize the utility of mass cytometry for identifying cell subsets that capture patient-specific disease attributes in the fields of pulmonology, neonatology, and virology. The studies by Abraham et al. (14) and Vendrame et al. (15) apply visualization and statistical tools in novel combinations to interpret high-dimensional data, while the manuscript by Leelatian et al. (16) describes a standardized protocol to derive isolated cancer cells from solid tissue for analysis by mass cytometry. Yao et al. (11) demonstrate the utility of multiparameter profiling of airway inflammatory cells in patients with cystic fibrosis (CF) to better understand the complex interactions between an individual’s immune state and disease severity. Using a novel assay for the mass cytometry analysis of airway inflammatory cells, the authors identified significant differences in the frequency of immune cell subsets in sputum collected from patients with CF, patients with asthma, and healthy controls. Interestingly, within each group substantial variability was observed when stimulating airway monocytes with lipopolysaccharide. These findings provide the basis for future work relating patient-specific signatures of airway inflammatory cells to disease progression and severity. Strauss-Albee et al. (13) focus on the deep immune profiling of umbilical cord blood samples to better define the natural killer (NK) cell repertoire and functional capacity of newborns. The authors provide a comprehensive overview of neonatal NK cell subsets and their functional attributes. Such characterization is important to better understand disease processes that engage the innate immune system of neonates who are uniquely vulnerable to infections and are unable to mount an efficient immune response to vaccination. In a third example emphasizing a translational application of mass cytometry, Corneau et al. (12) examine the cell cycle of CD41 T cells in the setting of HIV infection. Using a combination of cell cycle, differentiation, activation and exhaustion markers, they provide a more nuanced view of the effects of HIV infection on CD41 T cell cycling and question the traditional definitions of “resting” CD41 T cells. These results have potential clinical implications, as resting CD4 1 T cells are a reservoir for HIV infection difficult to target with commonly used treatments for HIV. Visualization of multiple cellular attributes across many cell subsets and robust statistical interpretation of high dimensional data remain critical challenges in implementing mass cytometry in clinical studies. The studies by Vendrame et al. (15) and Abraham et al. (14) illustrate these points. Vendrame et al. leverage the distinct strengths of existing computational approaches (i.e., viSNE (17) and citrus (18)] combined with custommade statistical tools (i.e., correspondence analysis and Friedman–Rafsky significance test) to extensively explore the effects of cytokines on human NK cell phenotype and function. Abraham et al. (14) introduce a radial visualization method called RADVIS, as an elegant
[1]
C. Blish,et al.
The newborn human NK cell repertoire is phenotypically formed but functionally reduced
,
2017,
Cytometry. Part B, Clinical cytometry.
[2]
S. Holmes,et al.
Mass Cytometry Analytical Approaches Reveal Cytokine‐Induced Changes in Natural Killer Cells
,
2017,
Cytometry. Part B, Clinical cytometry.
[3]
G. Nolan,et al.
Mass cytometry: The time to settle down
,
2017,
Cytometry Part A.
[4]
B. Gerrits,et al.
Exploring Glucocorticoid Receptor Agonists Mechanism of Action Through Mass Cytometry and Radial Visualizations
,
2017,
Cytometry. Part B, Clinical cytometry.
[5]
C. Katlama,et al.
Comprehensive Mass Cytometry Analysis of Cell Cycle, Activation, and Coinhibitory Receptors Expression in CD4 T Cells from Healthy and HIV‐Infected Individuals
,
2017,
Cytometry. Part B, Clinical cytometry.
[6]
Smita Krishnaswamy,et al.
Multiparameter Single Cell Profiling of Airway Inflammatory Cells
,
2017,
Cytometry. Part B, Clinical cytometry.
[7]
Rebecca A. Ihrie,et al.
Single cell analysis of human tissues and solid tumors with mass cytometry
,
2017,
Cytometry. Part B, Clinical cytometry.
[8]
E. Newell,et al.
Mass cytometry: blessed with the curse of dimensionality
,
2016,
Nature Immunology.
[9]
G. Nolan,et al.
Mass Cytometry: Single Cells, Many Features
,
2016,
Cell.
[10]
Antoni Ribas,et al.
Single-cell analysis tools for drug discovery and development
,
2015,
Nature Reviews Drug Discovery.
[11]
G. Nolan,et al.
Patient-specific Immune States before Surgery Are Strong Correlates of Surgical Recovery
,
2015,
Anesthesiology.
[12]
A. Tárnok.
Revisiting the crystal ball – high content single cells analysis as predictor of recovery
,
2015,
Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[13]
Stuart B. Goodman,et al.
Clinical recovery from surgery correlates with single-cell immune signatures
,
2014,
Science Translational Medicine.
[14]
Greg Finak,et al.
Critical assessment of automated flow cytometry data analysis techniques
,
2013,
Nature Methods.
[15]
S. Shen-Orr,et al.
New tools for classification and monitoring of autoimmune diseases
,
2012,
Nature Reviews Rheumatology.
[16]
Sean C. Bendall,et al.
Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum
,
2011,
Science.
[17]
G. Cutting.
Modifier genes in Mendelian disorders: the example of cystic fibrosis
,
2010,
Annals of the New York Academy of Sciences.
[18]
O. Ornatsky,et al.
Mass cytometry: technique for real time single cell multitarget immunoassay based on inductively coupled plasma time-of-flight mass spectrometry.
,
2009,
Analytical chemistry.
[19]
D. Andersen.
CYSTIC FIBROSIS OF THE PANCREAS AND ITS RELATION TO CELIAC DISEASE: A CLINICAL AND PATHOLOGIC STUDY
,
1938
.
[20]
Rebecca A. Ihrie,et al.
Single Cell Analysis of Human Tissues and Solid Tumors with Mass Cytometry.
,
2017,
Cytometry. Part B, Clinical cytometry.
[21]
R. Lewis.
Time to settle down
,
1991
.